Latest News
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
30 September 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) revealed on Wednesday that it has achieved positive 48-week Phase 2b results for EloraTZP, its investigational combination of eloralintide and tirzepatide, showing greater weight ...
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
30 September 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Wednesday announced positive Phase 2b results for tulisokibart, an investigational anti-TL1A monoclonal antibody, in patients with...
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
30 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for fenebrutinib under priorit...
Takeda reports positive Phase 3 psoriasis results for zasocitinib versus deucravacitinib
30 September 2026 - Japanese pharmaceutical company Takeda (TSE:4502) (NYSE:TAK) on Wednesday reported Phase 3 results showing that zasocitinib achieved statistically superior efficacy versus deucravacitinib across the primary and all key secondary e...
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
30 September 2026 - Belgian biopharmaceutical company Oxurion NV (Euronext Brussels:OXUR) announced on Wednesday that it has entered into exclusive negotiations to acquire the business and operating assets of Eclevar, a French contract research organ...